Figure 6. The relationship between DNA methylation signature and clinical response to immunotherapy investigated in GSE119144 cohort. (A) Relapse-free survival curves comparing high-risk with low-risk groups in NSCLC patients received anti-PD-1/PD-L1 therapies, according to DNAm-based risk score from validation set. (B) Proportion of clinical benefit to immunotherapy in the indicated groups stratified by our DNAm signature (DCB: durable clinical benefit and NDB: no durable benefit). (C) Time-dependent ROC curves for DNAm-based risk score, TMB, and risk score combined with TMB. (D) RFS curves of NSCLC patients with combinations of risk score and TMB.